Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a phase III, multi-center, double-blind randomized controlled trial assessing the
efficacy and safety of concurrent mitomycin C/5-Fu chemotherapy and long-course IMRT combined
with PD-1 antibody Sintilimab for locally advanced anal canal squamous carcinoma patients, by
comparing an experiment group (traditional chemoradiotherapy with PD-1 antibody Sintilimab)
with a control group (traditional treatment without Sintilimab).